Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure.
Gerd R BurmesterPeter NashBruce E SandsKim PappLori StockertThomas V JonesHuaming TanAnn MadsenHernan ValdezStanley B CohenPublished in: RMD open (2021)
The tofacitinib safety profile in this analysis was generally consistent across diseases and with longer term follow-up compared with previous analyses.